Cellectis S.A. (EPA:ALCLS)
3.330
-0.080 (-2.35%)
Oct 20, 2025, 1:45 PM CET
Cellectis Revenue
Cellectis had revenue of $18.19 million USD in the quarter ending June 30, 2025, with 91.44% growth. This brings the company's revenue in the last twelve months to $63.44 million, up 223.09% year-over-year. In the year 2024, Cellectis had annual revenue of $49.22 million with 435.37% growth.
Revenue (ttm)
$63.44M
Revenue Growth
+223.09%
P/S Ratio
4.57
Revenue / Employee
$285.76K
Employees
222
Market Cap
246.63M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sanofi | 45.74B |
EssilorLuxottica Société anonyme | 27.24B |
Eurofins Scientific SE | 7.14B |
emeis Société anonyme | 5.77B |
Clariane SE | 5.31B |
bioMérieux | 4.12B |
Ipsen | 3.76B |
Sartorius Stedim Biotech | 2.95B |
Cellectis News
- 2 days ago - CLLS: Analyst Raises Price Target Significantly for Cellectis | CLLS Stock News - GuruFocus
- 3 days ago - Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL - GlobeNewsWire
- 3 days ago - Top 2 Health Care Stocks That May Keep You Up At Night This Month - Benzinga
- 4 days ago - Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers - GlobeNewsWire
- 5 days ago - Allogene licensor Cellectis faces patent lawsuit in the U.S. - Seeking Alpha
- 13 days ago - Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress - GlobeNewsWire
- 7 weeks ago - Top 5 Biotech Stocks With Strong Momentum - Benzinga
- 2 months ago - Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript - Seeking Alpha